A Randomised, First-in-human, Double-blinded, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of CP1050 in Healthy Subjects; Including the Effect of Food and Gender on the Pharmacokinetics and Pharmacodynamics of a Single Dose of CP1050 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs CP 1050 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Curadim Pharma
- 17 Sep 2019 Status changed from suspended to completed.
- 07 Feb 2019 Status changed from recruiting to suspended.
- 20 Feb 2018 New trial record